Peptides are short chains of amino acids with different roles in the body. Explore the research behind individual compounds, what it can tell us, and the questions to work through with the treating clinical team.
What Are They?
By Jed Ryan, Founder and CEO · Published · Editorial update
Peptides are a broad family of molecules. Some act as signals between cells; others are designed to interact with particular biological targets. Their effects depend on the compound, how it is given and the condition being treated.
There is good reason to study these pathways, but a biological mechanism alone does not establish a treatment benefit. Evidence ranges from laboratory experiments to controlled human trials, and findings for one peptide cannot be applied to the whole category.
Strong Craft Regen helps you discuss your goals and records with the team at Innovita Clinic or another appropriate partner facility. The treating clinician assesses suitability, alternatives, risks and follow-up for the specific option being considered.
Questions to work through before considering a protocol include:
Examples from the research, with very different levels of evidence. Inclusion here does not mean each compound is available or suitable for you.
A small retrospective knee-pain report described symptom improvement without a control group. It cannot establish tissue repair or predict an individual result. Read the report.
Telomere changes have been studied in cultured human cells. Cell findings do not establish longer life or clinical benefit in people. Read the cell study.
A dry-eye trial of an eye-drop formulation missed its primary endpoints but found some secondary improvements. Those results do not establish benefits from injectable TB-500. Read the trial.
Studied in specific immune-related conditions. A large sepsis trial found no clear reduction in 28-day mortality, showing why the condition and outcome matter. Read the trial.
A 2023 randomized obesity trial found substantial weight loss; gastrointestinal side effects were common. Trial results apply to the tested product and population. Read the trial.
MOTS-c has mouse metabolic research. SS-31 (elamipretide), as Forzinity, received FDA accelerated approval to improve muscle strength in Barth syndrome patients weighing at least 30 kg. Neither finding establishes general anti-aging benefits.
Your goals guide the conversation. The evidence needs to match the proposed compound, condition and outcome.
Epithalon and MOTS-c illustrate interest in telomeres and metabolism. Much of that work examines cells or animals. A change in a laboratory marker does not establish slower aging or a longer, healthier life.
Tissue-repair research includes laboratory studies and early human observations. Pain relief, wound closure and structural tissue repair are different outcomes. A clinician needs to assess which, if any, is supported for the proposed use.
Thymosin Alpha-1 and retatrutide address different biological targets. Trials in sepsis or obesity answer specific questions; they do not show that peptides generally improve immunity or balance hormones.
Start with the exact peptide and the outcome being measured. A controlled human trial, an uncontrolled patient report and a cell experiment answer different questions. The linked studies show both promising findings and important limits.
Access also depends on the exact product and the rules where treatment takes place. In the United States, compounded drugs are not FDA-approved. Compounding and product approval are different questions; a clinician needs to check the applicable pathway.
Explore the ResearchFrom the first conversation to clinical assessment and, where appropriate, treatment. We help you understand the next step.
An exploratory conversation with Jed, for us to understand what you've been dealing with and how we can best help.
Discuss your records and goals with the clinical team, with scientific input from Dr. Adas Darinskas where appropriate. The treating physician assesses whether a treatment is suitable.
If treatment is appropriate, the treating clinical team explains the proposed plan, alternatives, uncertainties and follow-up. SCR helps coordinate the practical next steps.
Treatment location and availability depend on clinical assessment and local requirements. We help with scheduling and travel information; the treating team is responsible for medical care.
Client stories and testimonials, coming soon.
We're gathering stories from clients who've been through peptide protocols. Check back soon, or reach out to talk with the team about client experiences.
Start the Conversation